September 24, 2025|Access to Medicines, Health JusticeActivists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries Press Statement: For Immediate Release 24 September 2025 Contact: Asia Russell, asia@healthgap.org | +1 267 475 2645 Activists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries Health…
September 4, 2025|Access to Medicines, Funding the Fight, Health JusticeStatement by Health GAP in Response to State Department Announcement on Long Acting LenacapavirHealth GAP issued the following statement in response to an announcement by the U.S. State Department regarding Long Acting Lenacapavir (LEN-LA) for HIV pre exposure prophylaxis (PrEP): “Right now this administration’s illegal actions are the biggest obstacle to getting…
August 14, 2025|Access to Medicines, Health Justice278 Organizations and Individuals Demand Gilead CEO O’Day Commit to Rapid Application for Regulatory Approval of Long-Acting Lenacapavir for PrEP in all Low- and Middle-Income Countries Press Statement For Immediate Release: August 14 2025 Asia Russell, asia@healthgap.org | +1 267 475 2645 278 Organizations and Individuals Demand Gilead CEO O’Day Commit to Rapid Application for Regulatory Approval of Long-Acting Lenacapavir for PrEP in all Low- and Middle-Income Countries Gilead’s New…
June 18, 2025|Access to Medicines, Health JusticeGilead’s Greed Imperils Access to Newly FDA-Approved Breakthrough HIV Prevention Shot PRESS STATEMENT FOR IMMEDIATE RELEASE: July 18 2025 Contact for more information: Asia Russell | +1 267 475 2645 asia@healthgap.org Gilead’s Greed Imperils Global Access to Newly FDA-Approved Breakthrough HIV Prevention Shot While Estimates of HIV Infections…
December 2, 2024|Access to Medicines, Health JusticeOn World AIDS Day, Activist Coalition Demands Accelerated Access to Revolutionary HIV PreventionPRESS STATEMENT For Immediate Release: December 2, 2024 Activist Coalition Demands Accelerated Access to Revolutionary HIV Prevention Calls on Governments in the Global South to Break Trade and Intellectual Property Barriers and Take on Gilead’s Power Countdown to access campaign…
October 30, 2024|Access to MedicinesBavarian Nordic Mpox Shot Now Second-Most Expensive Vaccine UNICEF DistributesHealth Groups Urge Bavarian Nordic to Cut High Price of Mpox Vaccine, Quadruple Supply Under Existing UNICEF agreement. WASHINGTON D.C. — At $65 per dose, Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is the second-most expensive vaccine that UNICEF distributes, according…
October 2, 2024|Access to MedicinesGilead’s Access Strategy for Lenacapavir Will Unnecessarily Prolong the HIV Pandemic Activists Call for Affordable Access for all Low- and Middle-Income CountriesActivists reacted to Gilead’s announcement of plans to license lenacapavir, a long acting injectable for HIV prevention and treatment, to 6 generic companies that would supply 120 low- and middle-income countries. Lenacapavir has been shown to be highly effective in…
July 23, 2024|Access to MedicinesActivists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot(Munich) Today at AIDS 2024, a coalition of activists called for immediate global action to break Gilead’s monopoly on lenacapavir, in response to new data showing that generic lenacapavir can be produced at a price one thousand times less than…
February 6, 2024|Access to MedicinesStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for DolutegravirStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for Dolutegravir "Dolutegravir (DTG) is a lifesaving HIV treatment that can improve and extend the lives of people with HIV. DTG-based regimens are…
October 17, 2023|Access to MedicinesNew Analysis Reveals Shocking Extent of Unmet Need for Paxlovid in LMICs During COVID-19 EmergencyWashington, D.C. – In an analysis released today, Public Citizen and the Health Global Access Project (Health GAP) found that the number of people with high risk COVID-19 infections in low and middle income countries (LMICs) exceeded procured supply of…
